Genmab 6-K notes capital increase, insider trades

Genmab A/S submitted a Form 6-K for September 2025 that attaches two company announcements dated September 9, 2025.

Rhea-AI Filing Summary

Genmab A/S submitted a Form 6-K for September 2025 that attaches two company announcements dated September 9, 2025. One announcement describes a capital increase in Genmab resulting from employee warrant exercises. The other details transactions in Genmab shares and linked securities by managerial employees and their closely associated persons.

The Form 6-K is also deemed incorporated by reference into several existing Genmab registration statements on Form S-8, making these announcements part of those share-based compensation plans’ disclosure record.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the purpose of Genmab A/S’s September 2025 Form 6-K (GMAB)?

Genmab A/S uses this Form 6-K to furnish two company announcements dated September 9, 2025. One covers a capital increase from employee warrant exercises, and the other reports transactions in Genmab securities by managerial employees and closely associated persons.

What capital increase does Genmab A/S report in this Form 6-K?

Genmab reports a capital increase resulting from the exercise of employee warrants, as described in Exhibit 99.1. This reflects new shares issued under employee incentive programs, though specific share or amount details are contained in the referenced company announcement.

Which insider transactions are referenced in Genmab’s September 9, 2025 announcements?

Exhibit 99.2 refers to transactions involving Genmab shares and linked securities made by managerial employees and their closely associated persons. The filing notes these dealings are disclosed in a company announcement dated September 9, 2025, providing transparency on such trades.

How does this Genmab Form 6-K interact with the company’s Form S-8 registrations?

The Form 6-K is deemed incorporated by reference into Genmab’s existing Form S-8 registration statements. This means the information in the attached September 9, 2025 announcements becomes part of the disclosure for the company’s registered employee share-based compensation plans.

Which Genmab S-8 registration statements are updated by this Form 6-K?

The report is incorporated by reference into Genmab’s Form S-8 registration statements with file numbers 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876. This links the capital increase and insider transaction disclosures to those employee equity plan registrations.

Who signed the Genmab A/S September 2025 Form 6-K and in what role?

The Form 6-K was signed on behalf of Genmab A/S by Anthony Pagano. He is identified in the filing as Executive Vice President & Chief Financial Officer, confirming his authority to sign the report under the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/09/2025 - 03:02 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF SEPTEMBER 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated September 9, 2025: Capital Increase in Genmab as a Result of Employee Warrant Exercise
99.2			Company Announcement Dated September 9, 2025: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: SEPTEMBER 9, 2025